Search

Search Results

• PO:17:250 | Effectiveness and safety of the recombinant zoster vaccine in patients ≥18 years of age with systemic lupus Giulia Boschi¹, Sheryl A. Kluberg², Sophie E. Mayer², O'Mareen Spence³, Driss Oraichi³, Harry Seifert³, Omar Ali³, Huifeng Yun³, Andrew L. Simon⁴, Jenice S. Ko⁴, Caroline Hugh⁴, Meg Her⁴, Kathleen Shattuck⁴, Richard Platt², Aziza Jamal-Allial⁵, Djeneba Audrey Djibo⁶, Kimberly Daniels⁵, Qianli Ma⁷, Cheryl N. Mcmahill-Walraven⁶, Rachel P. Ogilvie⁸, Kristin Palmsten⁹, Mano Selvan⁷, Najat Ziyadeh⁸, Alexis Ogdie¹⁰, Michael George¹⁰ | ¹GSK Verona Italy; ²Harvard Medical School and the Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston; ³GSK Rockville; ⁴Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston; ⁵Carelon Research, Wilmington; ⁶CVS Health, Blue Bell; ⁷Humana Healthcare Research, Louisville; ⁸OptumInsight Life Sciences, Boston; ⁹HealthPartners Institute, Bloomington; ¹⁰University of Pennsylvania, Philadelphia, USA

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2166

  131

• PO:08:114 | The adjuvanted recombinant zoster vaccine is effective in preventing herpes zoster among patients ≥50 years of age with selected autoimmune diseases in the united states: a real-world database analysis (2018–2021) Rosaria Silvestri¹, Dagna Constenla², Germain Lonnet³, Emmanuel Aris³, Nathalie Servotte³, Ramsanjay Rk⁴, Agnes Mwakingwe-Omari², Huifeng Yun² | ¹GSK Verona, Italy; ²GSK Rockville, USA; ³GSK Wavre, Belgium; ⁴GSK Bengaluru, India

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2140

  149